ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling) * Aged 18 to 60 years * Non previously treated * With one and only one of the following adverse characteristics: ECOG performance status 2 or more, or Ann Arbor stage III or IV, or elevated LDH level * Negative HIV, HBV and HCV serologies (except vaccination) * With a minimum life expectancy of 3 months * Having previously signed a written informed consent Exclusion Criteria: * Any history of treated or non-treated indolent lymphoma. * T-cell lymphoma. * Central nervous system or meningeal involvement by lymphoma. * Any Contra-indication to any drug contained in the chemotherapy regimens. * Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Serious active disease (according to the investigator's decision). * Poor bone marrow reserve as defined by neutrophils \<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration. * Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study. * Childbearing woman. * Patients previously treated with an organ transplantation.